{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.7","upperLimit":"35.9","value":"24.7"},{"comment":"Not calculable/estimable due to insufficient number of events","groupId":"OG001","lowerLimit":"24.7","upperLimit":"NA","value":"30.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"Event-free survival (EFS) was defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy. If the specified event (disease progression, death, start of a new anti-leukemic treatment) did not occur, participants were censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"Safety Expansion Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the Main Cohort and the Safety Expansion Cohort with available data","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"months"}